{"entity":{"id":"origin-bio","kind":"company","name":"Origin Bio","aka":[],"tldr":"Origin is building the largest dataset of how individual cancer cells from real patients respond to drugs and genetic medicines, to license to pharma and AI companies.","summary":"Origin Bio generates patient-derived cancer single-cell datasets by screening the effects of drugs and genetic medicines on tumour cells under the control of what it calls DNA switches, and licenses the resulting data to pharmaceutical and AI drug-discovery companies training models of cancer biology. It is a Winter 2026 YC company with a small team; the dataset and any validation are at an early stage.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/origin-bio"},{"label":"Official website","url":"https://origin.bio"}],"tags":["yc"],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation"],"technologies":["single-cell-spatial","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"ai-software","website":"https://origin.bio","stage":"startup","ycBatch":"W26","investors":["y-combinator"],"funding":[]},"route":"/companies/origin-bio/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/"},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/"}],"company":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"}]}}